S&P Futures
3,828.25-14.25(-0.37%)Dow Futures
30,686.00-156.00(-0.51%)Nasdaq Futures
13,521.50+36.00(+0.27%)
MEI Pharma, Inc. (MEIP)
- Simply Wall St.
What Type Of Shareholders Own The Most Number of MEI Pharma, Inc. (NASDAQ:MEIP) Shares?
If you want to know who really controls MEI Pharma, Inc. ( NASDAQ:MEIP ), then you'll have to look at the makeup of its...
- PR Newswire
MEI Pharma Announces Expansion of Phase 1b Study Evaluating Zandelisib and Clinical Pipeline Update
MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced that the Phase 1b trial arm exploring zandelisib, an investigational selective phosphatidylinositol 3-kinase ("PI3K") delta inhibitor, in combination with zanubrutinib (marketed as BRUKINSA®), an inhibitor of Bruton's tyrosine kinase ("BTK") developed by BeiGene, Ltd. ("BeiGene"), completed the safety evaluation stage in patients with B-cell malignancies and is expanding into disease specific B-cell malignancy cohorts. The Safety Review Committee recommended moving forward with a dosing regimen found to be generally well tolerated and active following a planned safety analysis.
- Business Wire
MEI PHARMA INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of MEI Pharma, Inc. - MEIP
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC ("KSF"), announces that KSF has commenced an investigation into MEI Pharma, Inc. (NasdaqGS: MEIP).
